EHL Cell Clinic Appointed as Korea's First Clinic-Level Advanced Regenerative Medicine Institute

A Major Milestone for EHL Cell Clinic as a Certified Research Institute

The Korean Ministry of Health and Welfare recently announced the official list of additional Advanced Regenerative Medicine Institutes. Among the selected institutions, EHL Cell Clinic, under the management of EHL BIO, stands out significantly by being named the first clinic-level facility to serve as an official Cell Therapy Research Institute.

This achievement is more than just a prestigious recognition; it opens vital opportunities for the clinic to formally launch advanced regenerative medicine clinical research projects within a strict legal framework. Achieving this status serves as proof of the company's long-standing dedication to stem cell research, aiming to elevate treatment standards and enhance patient quality of life.

EHL BIO’s Standards and Readiness in Regenerative Medicine

EHL Cell Clinic's appointment as a research institute stems from the solid foundation of EHL BIO, which established Korea's first advanced human cell management system. The company boasts a robust team of over 85 researchers and facilities that meet Class 100 GMP (Good Manufacturing Practices) standards.

EHL BIO’s manufacturing facility has the capacity to process 6,000 lots per year, featuring a cell storage system in liquid nitrogen at -196°C to maintain the peak integrity of stem and immune cells. This readiness enables EHL Cell Clinic to conduct clinical research efficiently and with maximum safety in accordance with international standards.

This achievement is a testament to EHL Cell Clinic's commitment to stem cell research and a significant step for international regenerative medicine.

Global Collaboration and Future Treatment Plans

EHL BIO focuses not only on research within Korea but also maintains a network of over 100 partner hospitals in Korea and more than 50 worldwide. This includes collaborations with leading universities such as Chungnam National University and Yonsei University to co-develop cell therapy innovations.

Being designated as a regenerative medicine institute will accelerate the research and development of products like ADSTEM for atopic dermatitis and KDSTEM for chronic kidney disease, which are currently in various clinical trial stages. The goal is to provide new alternatives for recovering from chronic illnesses and promoting a better quality of life globally.

EHL Thailand Standard Service Procedures

For those interested in receiving services or participating in research, EHL Thailand provides a comprehensive Thai-speaking coordination team following a clear 6-step process. It begins with a consultation for medical document evaluation, followed by travel planning to the EHL Cell Clinic in Seoul, South Korea.

Upon arrival, clients undergo physical exams and cell collection for cultivation in the advanced GMP center before receiving personalized treatment plans. After returning to Thailand, the EHL Thailand team continues to monitor progress, ensuring the recovery process meets goals and improves long-term quality of life.